Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) Cost of Revenue (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Cost of Revenue for 12 consecutive years, with $883000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 14.44% year-over-year to $883000.0, compared with a TTM value of $3.2 million through Sep 2025, up 38.98%, and an annual FY2024 reading of $3.0 million, up 36.29% over the prior year.
  • Cost of Revenue was $883000.0 for Q3 2025 at Arcadia Biosciences, up from $824000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $3.8 million in Q4 2021 and bottomed at -$1.9 million in Q4 2022.
  • Average Cost of Revenue over 5 years is $1.2 million, with a median of $827000.0 recorded in 2024.
  • The sharpest move saw Cost of Revenue skyrocketed 548.48% in 2021, then crashed 151.47% in 2022.
  • Year by year, Cost of Revenue stood at $3.8 million in 2021, then plummeted by 151.47% to -$1.9 million in 2022, then skyrocketed by 109.21% to $178000.0 in 2023, then skyrocketed by 364.61% to $827000.0 in 2024, then grew by 6.77% to $883000.0 in 2025.
  • Business Quant data shows Cost of Revenue for RKDA at $883000.0 in Q3 2025, $824000.0 in Q2 2025, and $682000.0 in Q1 2025.